Poolbeg Announces POLB 001 TOPICAL Site Activation

AI SummaryClose X

Poolbeg Pharma PLC has announced a significant operational milestone with the successful activation of the first site for its POLB 001 TOPICAL clinical trial, which is investigating the drug as a potential preventative for Cytokine Release Syndrome (CRS) in approximately 30 relapsed/refractory multiple myeloma patients receiving teclistamab. Patient recruitment is now underway, and interim data is anticipated in summer 2026, with the company expressing optimism about POLB 001's potential to transform cancer immunotherapy by preventing this serious side effect.

Disclaimer*

UK 100

Latest directors dealings